Bristol Myers Squibb today announced that CheckMate -274, a pivotal Phase 3 trial evaluating Opdivo after surgery in patients with high-risk, muscle-invasive urothelial carcinoma, met its primary ...
SAN FRANCISCO -- Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of the use of neoadjuvant chemotherapy, according to updated ...
Adjuvant nivolumab improves DFS in MIBC patients, regardless of prior neoadjuvant chemotherapy, with a median DFS of 25.6 months versus 8.5 months with placebo. Overall survival rates at 24 and 36 ...
SAN FRANCISCO — New findings lend further support to adjuvant nivolumab (Opdivo) as a standard of care for patients with metastatic urothelial cancer. Extended follow-up data from the phase 3 ...
Adjuvant nivolumab maintains disease-free survival benefits at 5 years in patients with upper tract urothelial cancer or muscle-invasive bladder cancer at high risk for recurrence. Long-term follow-up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results